Angelini builds U.S. commercial ops via $4.1B Catalyst acquisition

A deal to acquire Catalyst for $4.1 billion will expand the U.S. footprint of Italian pharma Angelini, giving it commercial infrastructure and three approved drugs for rare diseases.

Angelini Pharma S.p.A. said it will pay $31.50 per share for Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), which derived $589 million in 2025 revenues from drugs including top seller Firdapse amifampridine phosphate and fast-growing Agamree vamorolone...